title: Somatostatin imaging of neuroendocrine-differentiated prostate cancer.
abstract: After prolonged androgen deprivation therapy, a subset of castrate-resistant prostate cancer patients will develop neuroendocrine prostate cancer (NEPC) associated with resistance to further hormonal therapy and frequent visceral metastases. Imaging the presence of somatostatin receptors on the cancer cell surface may provide a readily available, noninvasive means to distinguish adenocarcinoma from NEPC. This distinction is important for therapeutic decision making and may open the door for developing novel radionuclide targets for the treatment of this aggressive subtype of prostate cancer. We describe a case of NEPC successfully imaged using In-labeled octreotide.
authors.affiliation: From the *Department of Radiology and Biomedical Imaging, †Division of Hematology/Oncology, Department of Medicine, Departments of ‡Pathology, §Urology, and ∥Radiation Oncology, University of California San Francisco, San Francisco, CA.
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Hope
authors.forename: Rahul
authors.initials: R
authors.lastname: Aggarwal
authors.forename: Jeff P
authors.initials: JP
authors.lastname: Simko
authors.forename: Henry F
authors.initials: HF
authors.lastname: VanBrocklin
authors.forename: Charles J
authors.initials: CJ
authors.lastname: Ryan
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging*; D000368:Aged; D006801:Humans; D007205:Indium Radioisotopes; D008297:Male; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging* / Q000473:pathology; D015282:Octreotide; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals
chemical_list: D007205:Indium Radioisotopes; D019275:Radiopharmaceuticals; D015282:Octreotide